Preferred IUPAC name
DMA, DMAC, DMAc 
ECHA InfoCard 100.004.389
EC Number 204-826-4
C 4 H 9 N O
g·mol -1 Appearance
0.937 g mL -1
-20 °C (-4 °F; 253 K)
165.1 °C; 329.1 °F; 438.2 K
UV-vis (? max)
0.945 mPa s  Thermochemistry
178.2 J K -1 mol -1
-300.1 kJ mol -1
-2.5835--2.5805 MJ mol -1 Hazards
GHS signal word
H312, H319, H332, H360
63 °C (145 °F; 336 K)
490 °C (914 °F; 763 K)
Lethal dose or concentration (LD, LC):
2.24 g kg -1 (dermal, rabbit) 4.3 g kg -1 (oral, rat) 4.8 g/kg (oral, rat) 4.62 g/kg (oral, mouse) 
2475 ppm (rat, 1 hr)  US health exposure limits ( NIOSH):
TWA 10 ppm (35 mg/m 3) [skin] 
TWA 10 ppm (35 mg/m 3) [skin] 
300 ppm  Related compounds
Except where otherwise noted, data are given for materials in their
(at 25 °C [77 °F], 100 kPa).
( verify what is ?)
Dimethylacetamide ( DMAc or DMA) is the organic compound with the formula CH 3C(O)N(CH 3) 2. This colorless, water-miscible, high boiling liquid is commonly used as a polar solvent in organic synthesis. DMA is miscible with most other solvents, although it is poorly soluble in aliphatic hydrocarbons.
Synthesis & Production
Dimethylacetamide is produced industrially by the reaction of
dimethylamine with methyl acetate at a temperature of 90-110 °C and a pressure of 12-25 bar in the presence of sodium methoxide in jet loop reactors. 
The separation and purification of the product is carried out by multistage
distillation in rectification columns. DMA is obtained with 99% yield referred to methyl acetate. 
DMA may also be prepared by the reaction of
dimethylamine with acetic anhydride or acetic acid. Dehydration of the salt of dimethylamine and acetic acid also furnishes this compound:  CH 3CO 2H·HN(CH 3) 2 -> H 2O + CH 3CON(CH 3) 2
Reactions & Applications
The chemical reactions of dimethylacetamide are typical of
N, N-disubstituted amides. It will hydrolyze in the presence of acids:
CH 3CON(CH 3) 2 + H 2O + HCl -> CH 3COOH + (CH 3) 2NH 2 +Cl -
It is however resistant to bases. For this reason DMA is useful solvent for reactions involving strong bases such as
sodium hydroxide. 
Dimethylacetamide is commonly used as a solvent for fibers (e.g.,
polyacrylonitrile, spandex) or in the adhesive industry. It is also employed in the production of  pharmaceuticals and plasticizers as a reaction medium. It is an important Lewis base used to establish the ECW model.
Dimethylacetamide is also used as an
excipient in drugs, e.g. in Vumon ( teniposide), Busulfex ( busulfan) or Amsidine ( amsacrine).
Dimethylacetamide is a medium potency reproductive toxicant (
toxic for reproduction, category 1B) and may damage fertility or the unborn child. It is harmful in contact with skin or if inhaled, and causes serious eye irritation.
Dimethylacetamide can cause
hepatotoxicity, including occupational dimethylacetamide exposure-induced hepatotoxicity.    At high doses (400 mg/kg bodyweight daily), dimethylacetamide causes effects on the  central nervous system (e.g. depression, hallucinations and delusion).   
Dimethylacetamide may be incompatible with
polycarbonate or ABS. Devices (e.g. syringes) that contain polycarbonate or ABS can dissolve when coming into contact with dimethylacetamide. 
In 2011, dimethylacetamide was identified in the EU as a
Substance of very high concern (SVHC) because of its reproductive toxicity. In 2014, the European Commission has started an investigation to restrict the use of dimethylacetamide in the EU according to  REACH. 
In 2015, the CNESST (Committee on Standards, Equity, Health and Safety at Work in
Quebec) has adopted a tightened classification of dimethylacetamide: 
GHS hazard statement
Suspected of damaging fertility or the unborn child (H361)
Specific target organ toxicity - repeated exposure
May cause damage to organs through prolonged or repeated exposure (H373)
Serious eye damage/eye irritation
Causes serious eye irritation (H319)
Acute toxicity - inhalation
Toxic if inhaled (H331)
Specific target organ toxicity - single exposure - narcotic effects
May cause drowsiness or dizziness (H336)
Combustible liquid (H227)
Munro, D. D.; Stoughton, R. B. (1965). "Dimethylacetamide (DMAC) and Dimethylformamide (DMFA). Effect on Percutaneous Absorption". Archives of Dermatology. 92 (5): 585-586. doi: 10.1001/archderm.1965.01600170101020. PMID 5844405.
^ Iloukhani, H., and K. Khanlarzadeh. "Densities, viscosities, and refractive indices for binary and ternary mixtures of N, N-dimethylacetamide (1)+ 2-methylbutan-2-ol (2)+ ethyl acetate (3) at 298.15 K for m liquid region and at ambient pressure." Journal of Chemical & Engineering Data 51.4 (2006): 1226-1231.
^ a b c
NIOSH Pocket Guide to Chemical Hazards. "#0218". National Institute for Occupational Safety and Health (NIOSH).
^ a b
"Dimethyl acetamide". Immediately Dangerous to Life and Health Concentrations (IDLH). National Institute for Occupational Safety and Health (NIOSH).
^ a b
Grafmans, Horst; Maas, Steffen; Weck, Alexander; Rütter, Heinz; Schulz, Michael; Ross, Karl-Heinz. "Method for the production of n,n-dimethylacetamide (DMAC)". Google Patents. BASF SE . Retrieved 2019.
^ a b
Cheung, H.; Tanke, R. S.; Torrence, G. P. "Acetic Acid". . Weinheim: Wiley-VCH. Ullmann's Encyclopedia of Industrial Chemistry doi: 10.1002/14356007.a01_045.pub2. CS1 maint: multiple names: authors list ( link)
Zen, S.; Kaji, E. (1977). "Dimethyl nitrosuccinate". . Organic Syntheses 57: 60. CS1 maint: multiple names: authors list ( link) ; Collective Volume, 6, p. 503
European Chemicals Agency, Opinion on N,N-Dimethylacetamide (DMAC), 12 September 2014
^ a b U.S. Department of Health and Human Services & U.S. Department of Labor (1978)
Occupational Health Guideline for Dimethyl Acetamide. Now: Occupational Health Guideline for Chemical Hazards. DHHS (NIOSH) Publication Number 81-123. January 1981. The National Institute for Occupational Safety and Health (NIOSH).
Baum, S. L.; Suruda, A. J. (1997). "Toxic Hepatitis from Dimethylacetamide". International Journal of Occupational and Environmental Health. 3 (1): 1-4. doi: 10.1179/oeh.1922.214.171.124. PMID 9891094.
Lee, C.-Y.; Jung, S.-J.; Kim, S.-A.; Park, K.-S.; Ha, B.-G. (2006). "Incidence of dimethylacetamide induced hepatic injury among new employees in a cohort of elastane fibre workers". Occupational and Environmental Medicine. 63 (10): 688-693. doi: 10.1136/oem.2005.023580. PMC . 2078052 PMID 16728503.
Gong, W.; Liu, X.; Zhu, B. (2016). "Dimethylacetamide-induced occupational toxic hepatitis with a short term recurrence: a rare case report". Journal of Thoracic Disease. 8 (6): E408-E411. doi: 10.21037/jtd.2016.04.44. PMC . 4885965 PMID 27293868.
Weiss, A. J.; Jackson, L. G.; Carabasi, R. A.; Mancall, E. L.; White, J. C. (1962). "A Phase I Study of Dimethylacetamide". Cancer Chemotherapy Reports. 16 (February 1962): 477-485. PMID 14005853.
Weiss, A. J.; Mancall, E. L.; Koltes, J. A.; White, J. C.; Jackson, L. G. (1962). "Dimethylacetamide: A Hitherto Unrecognized Hallucinogenic Agent". Science. 136 (3511): 151-152. doi: 10.1126/science.136.3511.151. PMID 14005854.
FDA warns health care professionals not to use Treanda Injection (solution) with closed system transfer devices, adapters, and syringes containing polycarbonate or acrylonitrile-butadiene-styrene - 10 March 2015
Agreement of the Member State Committee on the Identification of N,N-Dimethylacetamide (DMAC) as a Substance of Very High Concern - Adopted on 24 November 2011
Official Journal of the European Union, 19.8.2014, Commission Regulation (EU) No 895/2014
^ Commission des normes, de l'équité, de la santé et de la sécurité du travail (CNESST), Quebec, Canada:
WHMIS 2015 classification of N,N-Dimethylacetamide